PRINCETON, N.J. (
(BMY - Get Report)
acquired worldwide rights to an experimental rheumatoid arthritis drug from privately held
, the companies announced Tuesday.
The drug, ALD518, is an injectable monoclonal antibody that targets and blocks the production of IL-6, a molecule that plays role in the inflammation, swelling, pain and destruction of bone joints. The drug has completed a phase IIa study, to date.
ALD518 shares the same mechanism as
rheumatoid arthritis drug Actemra, which is currently under review by the U.S. Food and Drug Administration.
In exchange for worldwide rights to ALD518 for all indications but cancer, Alder receives from Bristol $85 million in cash up front, and is eligible for an additional $764 million in future development and regulatory milestone. Alder will also receive royalties based on future ALD518 sales and Bristol may invest up to $20 million in a possible Alder initial public offering.
Bristol already markets a rheumatoid arthritis drug, Orencia, and has another oral drug in phase II studies, according to BioMedTracker.com
Speaking of oral rheumatoid arthritis drugs,
(RIGL - Get Report)
is still seeking a partner for its phase II drug candidate, R788.
Survey the RA Treatment Landscape
Doctors expect to prescribe modest amounts of two new biologic rheumatoid arthritis drugs from
Johnson & Johnson
over the next year, which means market share for existing drugs from
(AMGN - Get Report)
should remain relatively protected.
That's headline conclusion from a survey of rheumatoid arthritis doctors published Tuesday by Sanford Bernstein.
The recent launches of J&J's Simponi and UCB's Cimzia are expected to help grow the overall RA treatment market, but market share for each drug is only expected to reach 9% and 7%, respectively over the next 12 months, the Bernstein survey finds.
"Adoption of the new entrants looks to be gradual, consistent with their lack of an established safety profile and challenges with formulary access," the Bernstein report says.